MX2022007441A - Inhibidores de proteína tirosina fosfatasa y sus métodos de uso. - Google Patents
Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.Info
- Publication number
- MX2022007441A MX2022007441A MX2022007441A MX2022007441A MX2022007441A MX 2022007441 A MX2022007441 A MX 2022007441A MX 2022007441 A MX2022007441 A MX 2022007441A MX 2022007441 A MX2022007441 A MX 2022007441A MX 2022007441 A MX2022007441 A MX 2022007441A
- Authority
- MX
- Mexico
- Prior art keywords
- protein tyrosine
- tyrosine phosphatase
- methods
- phosphatase inhibitors
- ptpn1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/65392—Five-membered rings containing two nitrogen atoms
- C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949613P | 2019-12-18 | 2019-12-18 | |
| PCT/US2020/066104 WO2021127499A1 (en) | 2019-12-18 | 2020-12-18 | Protein tyrosine phosphatase inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007441A true MX2022007441A (es) | 2022-09-02 |
Family
ID=74195125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007441A MX2022007441A (es) | 2019-12-18 | 2020-12-18 | Inhibidores de proteína tirosina fosfatasa y sus métodos de uso. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230019236A1 (https=) |
| EP (1) | EP4077291A1 (https=) |
| JP (2) | JP7751582B2 (https=) |
| CN (1) | CN116348455A (https=) |
| AU (1) | AU2020407648A1 (https=) |
| CA (1) | CA3162069A1 (https=) |
| MX (1) | MX2022007441A (https=) |
| WO (1) | WO2021127499A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4073242A4 (en) | 2019-12-12 | 2024-01-03 | Kumquat Biosciences Inc. | Compositions and methods for potentiating immune activity |
| WO2023086498A1 (en) * | 2021-11-11 | 2023-05-19 | Calico Life Sciences Llc | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| MX2024005656A (es) * | 2021-11-11 | 2024-08-06 | Calico Life Sciences Llc | Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos. |
| CN119790052A (zh) * | 2022-09-13 | 2025-04-08 | 金橘生物科技公司 | 苯并稠合的n-杂环及其用途 |
| PE20252789A1 (es) | 2023-05-24 | 2025-12-22 | Kumquat Biosciences Inc | Compuestos heterociclicos y usos de estos |
| KR20260040037A (ko) | 2023-07-14 | 2026-03-23 | 카톨리에케 유니버시테이트 루벤 | 암 및 대사 질병의 치료를 위한 신규 화합물 |
| CN119818693A (zh) * | 2023-10-13 | 2025-04-15 | 华东师范大学 | 一种用于前药给药系统的可裂解支链连接体化合物及其制备和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US162A (en) | 1837-04-17 | Island | ||
| US5212A (en) | 1847-07-31 | Richard m | ||
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| BR112020026086A2 (pt) * | 2018-06-21 | 2021-03-23 | Calico Life Sciences Llc | inibidores da proteína tirosina fosfatase e métodos de uso destes |
| IL286373B2 (en) * | 2019-03-14 | 2026-03-01 | Calico Life Sciences Llc | Protein tyrosine phosphate inhibitor compounds and uses thereof |
-
2020
- 2020-12-18 CA CA3162069A patent/CA3162069A1/en active Pending
- 2020-12-18 AU AU2020407648A patent/AU2020407648A1/en active Pending
- 2020-12-18 MX MX2022007441A patent/MX2022007441A/es unknown
- 2020-12-18 WO PCT/US2020/066104 patent/WO2021127499A1/en not_active Ceased
- 2020-12-18 JP JP2022538083A patent/JP7751582B2/ja active Active
- 2020-12-18 EP EP20845275.5A patent/EP4077291A1/en active Pending
- 2020-12-18 CN CN202080097033.6A patent/CN116348455A/zh active Pending
-
2022
- 2022-06-16 US US17/807,292 patent/US20230019236A1/en active Pending
-
2025
- 2025-09-26 JP JP2025159693A patent/JP2026004380A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7751582B2 (ja) | 2025-10-08 |
| CA3162069A1 (en) | 2021-06-24 |
| CN116348455A (zh) | 2023-06-27 |
| US20230019236A1 (en) | 2023-01-19 |
| JP2026004380A (ja) | 2026-01-14 |
| EP4077291A1 (en) | 2022-10-26 |
| AU2020407648A1 (en) | 2022-06-30 |
| WO2021127499A1 (en) | 2021-06-24 |
| JP2023507774A (ja) | 2023-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001723A1 (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
| CO2021000447A2 (es) | Inhibidores de proteína tirosina fosfatasa y sus métodos de uso | |
| MX2022007441A (es) | Inhibidores de proteína tirosina fosfatasa y sus métodos de uso. | |
| MX2023002953A (es) | Inhibidores de proteína tirosina fosfatasa y métodos para su uso. | |
| UY38999A (es) | Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| CL2021001490A1 (es) | Constructos de iarn modificados químicamente y usos de estos | |
| CR20240360A (es) | Inhibidores de proteína tirosina fosfatasa y usos de estos | |
| CO2021001472A2 (es) | Inhibidores de transglutaminasa 2 (tg2) | |
| CL2020001742A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| CL2021001488A1 (es) | Transposasa de piggybac mutada | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| MX2020014303A (es) | Inhibición de la proteína de union a creb (cbp). | |
| CL2020001089A1 (es) | Compuestos inhibidores de tirosina cinasa de bruton (btk). | |
| CL2023002120A1 (es) | Terapia combinada de un inhibidor de alk2 y un inhibidor de jak2 | |
| ECSP21042779A (es) | Moduladores de la expresión de irf5 | |
| MX2023012782A (es) | Composiciones de factor de crecimiento para el tratamiento de enfermedades oculares. |